Hemodynamics at Maximum Exercise and Exercise Recovery in Freshman Football Recruits at a BCS School

To determine if blood pressures assessed during max exercise and exercise recovery differ in Freshman football player recruits classified according to body mass index categories (BMICAT). A group of 107 freshman football recruits (mean age=18.2yrs, mean height=187.2 cm, mean weight = 103.0 kg, mean BMI=27.4 kg/meters squared, mean percent fat= 18.3%.) underwent graded exercise testing on a treadmill. Height and weight were assessed and BMI was calculated as weight (kg) / height (m) squared. All 97 subjects were classified as either “normal weight”(NW) (N=38), “overweight” (OW)(N=41) or “obese” (OB)(N=28) according to the National Institutes of Health guidelines. Body fat percentage (PCTFAT) was assessed using dual x-ray absorptiometry. Resting systolic (SBP) and diastolic (DBP) blood pressures were taken following a 3 minute rest period. Mean arterial pressure (MAP) was estimated as [.3(SBP-DBP)]+DBP. Pressures were also assessed at max exercise and at 1, 3, and 5 minutes post exercise. An analysis of covariance (ANCOVA) with PCTFAT as a covariate was used to determine if differences remained among BMICAT in adjusted values for max exercise and all recovery pressures. After ACOVA adjustment, all maximum and recovery pressures were different among BMICAT with statistical significance found at max exercise and 1 minute post exercise. After adjustment for PCTFAT, differences remain in blood pressures among BMI categories

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer : long-term survival results from the STAMPEDE trial

Background STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients. Methods We randomly allocated patients in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC + docetaxel. Metastatic disease burden was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox regression models, adjusted for stratification factors, with emphasis on restricted mean survival time where hazards were non-proportional. Results Between 05 October 2005 and 31 March 2013, 1086 M1 patients were randomised to receive SOC (n = 724) or SOC + docetaxel (n = 362). Metastatic burden was assessable for 830/1086 (76%) patients; 362 (44%) had low and 468 (56%) high metastatic burden. Median follow-up was 78.2 months. There were 494 deaths on SOC (41% more than the previous report). There was good evidence of benefit of docetaxel over SOC on OS (HR = 0.81, 95% CI 0.69–0.95, P = 0.009) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P = 0.827). Analysis of other outcomes found evidence of benefit for docetaxel over SOC in failure-free survival (HR = 0.66, 95% CI 0.57–0.76, P  0.5 in each case). There was no evidence that docetaxel resulted in late toxicity compared with SOC: after 1 year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-up at 1 year without prior progression). Conclusions The clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence that benefit differed by metastatic burden. We advocate that upfront docetaxel is considered for metastatic hormone naïve prostate cancer patients regardless of metastatic burden